Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Targeted plasma proteomics uncover novel proteins associated with KIF5A -linked SPG10 and ALS spectrum disorders
Orlacchio, Antonio , Munain, Adolfo López de, Vucic, Steve , Barakat, Tahsin Stefan , Petrucelli, Leonard , Prudencio, Mercedes , Weishaupt, Jochen H., Prudencio, Mercedes , Dulski, Jarosław , Boddapati, Arun Kumar , Risi, Barbara , Iruzubieta, Pablo , Fernández‐Torrón, Roberto , Castillo‐Triviño, Tamara , Munain, Adolfo López de, Padovani, Alessandro , Kaat, Laura Donker , Landers, John E. , Weishaupt, Jochen H. , Prokop, Andreas , Filosto, Massimiliano , Wszołek, Zbigniew K. , Pant, Devesh C.

No container title available | May 2, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.04.29.651203 Get It

Abstract KIF5A (Kinesin family member 5A) is a motor protein that functions as a key component of the axonal transport machinery. Variants in KIF5A are linked to several neurodegenerative diseases, mainly spastic paraplegia type 10 (SPG10), Charcot-Marie-Tooth disease type 2 (CMT2), and amyotrophic lateral sclerosis (ALS). These diseases share motor neuron involvement but vary significantly in clinical presentation, severity, and progression. KIF5A variants are mainly categorized into N-terminal variants associated with SPG10/CMT2 and C-terminal variants linked to ALS. This study utilized a novel multiplex NULISA targeted platform to analyze plasma proteome from KIF5A -linked SPG10, ALS patients and compared to healthy controls. Our results revealed distinct proteomic signatures, with significant alterations in proteins related to synaptic function, and inflammation. Notably, neurofilament light polypeptide, a biomarker for neurodegenerative diseases, was elevated in KIF5A ALS but not in SPG10 patients. Moreover, these findings can now be taken forward to gain mechanistic understanding of axonopathies linking to N- vs C-terminal KIF5A variants affecting both central and peripheral nervous systems.
Pulling Back the Curtain on Hospital Dementia Detection: Validation of the Informant‐Based Clinical Dementia Rating
Avelino‐Silva, Thiago Junqueira , Covinsky, Kenneth E. , Bertola, Laiss , Magaldi, Regina Miksian , Boyd, Cynthia M. , Carpenter, Christopher R. , Yassuda, Mônica Sanches, Suemoto, Cláudia Kimie , Group, the CHANGE Study, Aliberti, Márlon J R , Avelino-Silva, Thiago Junqueira , Carpenter, Christopher R , Suemoto, Claudia Kimie , Yassuda, Mônica Sanches, Group, the CHANGE Study

Journal of the American Geriatrics Society | May 2, 2025 | Volume: 73 | Issue: 8 | Pages: 2524-2530

10.1111/jgs.19494 | PMID 40317752 Get It

ABSTRACT Background Dementia often goes undetected in hospital settings, where cognitive assessments are challenging due to illness severity and delirium. This study aimed to (1) evaluate the accuracy of the Clinical Dementia Rating (CDR), based solely on knowledgeable informant reports, for detecting preexisting dementia and cognitive impairment in hospitalized patients compared to a gold‐standard diagnosis, (2) and compare its performance to the 16‐item Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE‐16). Methods This cross‐sectional study assessed consecutive patients aged ≥ 65 admitted to inpatient units from five hospitals in Brazil. The informant‐based CDR was administered to knowledgeable informants within 48 h of admission, capturing patients' cognitive status 3 months before hospitalization to avoid the influence of acute cognitive impairments. Blinded experts provided a gold standard clinical diagnosis of dementia or cognitive impairment no dementia (CIND) based on a 90‐min comprehensive assessment, including a standardized neuropsychology battery. Areas under the curve (AUC) examined diagnostic accuracy. Results Of 65 participants (mean age = 79.4 years; women = 54%), 34% had dementia and 32% had CIND . Compared to the gold standard, the informant‐based CDR showed excellent diagnostic accuracy for detecting dementia ( AUC = 0.92; 95% confidence interval [ CI ] = 0.86–0.98) and cognitive impairment ( AUC = 0.93; 95% CI = 0.88–0.98), with a cutoff of ≥ 1 showing 98% specificity for dementia and a cutoff of ≥ 0.5 showing 98% sensitivity for cognitive impairment. Compared to the IQCODE ‐16, the informant‐based CDR had similar performance in detecting dementia and a nonsignificant slight advantage in identifying cognitive impairment ( AUC = 0.93 vs. 0.84, p = 0.069), reducing unrecognized cognitive impairment based on medical record documentation from 70% to 2%. Conclusions Informant‐based CDR is a valid and efficient tool for detecting dementia and cognitive impairment in hospitalized older adults, supporting early diagnosis and guiding multidisciplinary interventions in acute care. Its use in routine hospitals may help clinicians reduce undetected cognitive impairment, enhance decision making, and improve patient care.
3D‐Printed Microfluidic Platform for Creating Porous Nanofibrous Microspheres to Regulate Cell Response and Enhance Tissue Regeneration
Lee, Dong-Hee , Tran, Huy Quang , Sharma, Navatha Shree , Yan, Zishuo , Killeen, Amy C., Reinhardt, Richard A., Zhu, Wuqiang , Xie, Jingwei , Zhu, Wuqiang , Andrabi, Syed Muntazir , Xie, Jingwei

Small | May 2, 2025 | Volume: 21 | Issue: 41 | Pages: No page available

10.1002/smll.202502033 | PMID 40318101 Get It

Abstract Porous nanofibrous microspheres (PNMs) present a versatile and minimally invasive strategy for tissue regeneration, combining biomimetic morphology, tunable structure, and injectability. While self‐assembly and co‐axial electrospray are explored for PNM fabrication, these methods are limited in compositional versatility and production scalability. Here, a 3D‐printed microfluidic platform is presented that enables large‐scale fabrication of PNMs with precise control over size, pore architecture, and morphology. PNMs can be functionalized with bioactive molecules through UV crosslinking, enhancing their regenerative potential by promoting osteogenesis in human bone marrow stromal cells (hBMSCs), angiogenesis in human umbilical vein endothelial cells (HUVECs), and exerting anti‐inflammatory effects on macrophages. Subcutaneous implantation in rats demonstrates that PNMs support cell infiltration, minimize fibrosis, and facilitate tissue integration, achieving complete cell penetration and tissue incorporation within 14 days. These findings establish PNMs as versatile, scalable, and customizable platforms, ideal for applications as injectable drugs or cell carriers, as well as powders, offering promising solutions for wound healing and tissue regeneration.
Sleep trajectories across three cognitive‐aging pathways in community older adults
Oryshkewych, Nina , Wheeler, Bradley J. , Butters, Meryl A. , Buysse, Daniel J., Leng, Yue , Yu, Lan , Soehner, Adriane M. , Wallace, Meredith L. , Tapia, Amanda L. , Zaheed, Afsara B. , Buysse, Daniel J. , Barnes, Lisa L. , Lim, Andrew S. P.

Alzheimer's & Dementia | May 2, 2025 | Volume: 21 | Issue: 5 | Pages: No page available

10.1002/alz.70159 | PMID 40317639 Get It

AbstractINTRODUCTIONComparing sleep and rest–activity rhythms across different cognitive aging pathways can identify novel risk factors and potential mechanisms. However, our current understanding is restricted by differences in sleep measurement, limited longitudinal data, and heterogeneous cognitive aging processes.METHODSWe applied cubic splines to longitudinal self‐reported sleep and actigraphy data from 1449 participants in the Rush Memory and Aging Project and quantified differences in the levels and trajectories of sleep amount, regularity, and timing within and between three cognitive aging pathways: normal, stable mild cognitive impairment, dementia.RESULTSSleep amount was lowest in the dementia pathway prior to cognitive impairment but increased with age, most rapidly after dementia. Regularity declined across all pathways, most rapidly after cognitive diagnoses. Timing advanced across all pathways.DISCUSSIONShorter sleep amount in cognitively healthy older adults may be a risk factor or prodromal indicator of dementia, while longer sleep amounts and decreasing regularity may reflect neurodegeneration.Highlights We quantified longitudinal changes in sleep across three cognitive‐aging pathways. We incorporated both subjective and objective measures of sleep health. Self‐report duration increased noticeably from before to after cognitive diagnosis. Sleep irregularity increased most prominently after cognitive diagnosis. Advances in sleep timing occurred in both normal and pathological aging.
A Novel Presentation and Variable Phenotypic Spectrum of Homozygous Start‐Loss Variant in LYRM7‐Associated Mitochondrial Complex III Deficiency
Luke, Noel Deep , Nair, Aditya , Sivadasan, Ajith , Thomas, Maya , Yoganathan, Sangeetha , Aaron, Rekha , Jasper, Anitha , Mannam, Pavithra , Daniel, Roshan , Aaron, Rekha , Daniel, Roshan , Danda, Sumita , Muthusamy, Karthik

American Journal of Medical Genetics Part A | May 2, 2025 | Volume: 197 | Issue: 9 | Pages: No page available

10.1002/ajmg.a.64105 | PMID 40317892 Get It

ABSTRACT LYRM7‐associated mitochondrial complex III deficiency has classically been described in the literature as a childhood‐onset episodic leukoencephalopathy with neuroimaging findings of cavitating periventricular and subcortical white matter loss. We describe the heterogeneous clinical and neuroimaging profile of six individuals from south India with the specific homozygous pathogenic variant in the LYRM7 gene (c.2T>C, (p.Met1?)). This is a retrospective case series featuring six cases (four pediatric, one adult, and one adolescent‐onset) with the pathogenic start loss LYRM7 variant. The spectrum of neurologic manifestations and brain imaging findings documented over multiple clinic visits was analyzed and described. Vision loss and lactic acidosis were seen in all but one individual. A novel phenotype with adult‐onset isolated bilateral simultaneous optic neuropathy was noted. Characteristic cavitating leukoencephalopathy in supratentorial white matter was seen in the brain MRI of three out of six individuals. A comprehensive description of our cases along with the previously published cases is provided in the table highlighting the clinical and imaging variability and the disease course. The phenotype of adult‐onset isolated acute optic neuropathy can be a manifestation of LYRM7‐related mitochondrial disorder. LYRM7‐associated Mitochondrial Complex III deficiency should be considered in the differential diagnosis of para‐ and post‐infectious demyelinating/inflammatory disorders, especially if there is a background of variable developmental delay, recurrence of the episodes, family history, cystic changes in cerebral white matter on imaging, or poor response to immunomodulation. The case series also exemplifies the intra‐and inter‐familial variability seen with this rare disorder.
ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease
Limketkai, Berkeley N. , McClain, Craig J. , Abdelmalek, Manal F. , McClain, Craig J , Singal, Ashwani K. , Wong, Robert J. , Dasarathy, Srinivasan , Neuschwander‐Tetri, Brent A. , Petrey, Jessica

American Journal of Gastroenterology | May 2, 2025 | Volume: 120 | Issue: 5 | Pages: 950-972

10.14309/ajg.0000000000003379 | PMID 40314389 Get It

Malnutrition, defined as deficiency, excess, or imbalance of nutrients, is a common complication in patients with liver disease, especially those with cirrhosis. Malnutrition may present as an isolated micronutrient deficiency, such as zinc deficiency, and it commonly presents as frailty and/or sarcopenia in patients with advanced liver disease. Patients with cirrhosis and/or alcohol-associated hepatitis should be assessed for malnutrition because it adversely affects patient outcomes including mortality, as well as waitlist and posttransplant outcomes among liver transplant candidates. The prevalence of malnutrition varies based on the method of assessment and disease severity, being higher in those with advanced liver disease. Among stable outpatients with cirrhosis, counseling should be done to eat small frequent meals, a night-time snack between 7 PM and 10 PM, and 2 or more cups of coffee daily. In selected patients with metabolic dysfunction-associated steatohepatitis, vitamin E 800 IU/d should be provided. Among hospitalized patients with cirrhosis, nutritional supplementation preferably by enteral route should be implemented in those with poor oral intake of daily requirements of proteins and/or calories. Protein intake should not be restricted including patients with decompensated cirrhosis and hepatic encephalopathy. A vegetable source of protein seems to be better tolerated than an animal source of protein in patients with hepatic encephalopathy. Branched chain amino acids augment the efficacy of lactulose and rifaximin in the treatment of hepatic encephalopathy. Level of evidence and strength of recommendations were evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations system. This guideline was developed under the auspices of the American College of Gastroenterology Practice Parameters Committee.
Disparities in technology utilization among youth with type 1 diabetes across diverse racial and socioeconomic backgrounds
Nofal, Alaa Al , Hassan, Doha, Rajjo, Tamim , Heien, Herbert C., Al Nofal, Alaa , Hassan, Doha, McCoy, Rozalina G.

BMJ Open Diabetes Research & Care | May 2, 2025 | Volume: 13 | Issue: 3 | Pages: e004935

10.1136/bmjdrc-2025-004935 | PMID 40316315 Get It

Background Previous studies have demonstrated disparities in the utilization of diabetes technology among youth with type 1 diabetes (T1D) based on race and socioeconomic status (SES). Few studies have examined these differences on a national scale or among youth with commercial health insurance. Aim To investigate differences in the fill rates of insulin pumps and continuous glucose monitors (CGMs) among commercially insured children with T1D across diverse racial and SES groups. Methods Using medical and pharmacy claims included in the OptumLabs Data Warehouse, we calculated the proportion of youth <18 years with T1D who had a fill for an insulin pump or a CGM, overall and stratified by race/ethnicity and annual household income, between 2011 and 2021. Results Among 13,246 youth with T1D, 36.1% had CGM and 30.9% had pump fills. White youth had higher CGM and pump fills than black (CGMs: 35.8% vs 22.5%; pumps: 31.9% vs 21.2%, p<0.001) and Hispanic (CGMs: 35.8% vs 32.6%, p=0.047; pumps: 31.9% vs 25.0%, p<0.001). Youth from households with income <US$40,000 had lower CGM and pump fills than those with income ≥US$200,000 (CGM 25.4% vs 43.8%; pumps: 22.4% vs 38.8%, p<0.001). Within similar incomes <US$40,000, black youth had fewer CGM and pump fills than white youth (CGM: 15.2% vs 27.9%, p=0.006; pumps: 12.9% vs 25.5%, p=0.004). This racial difference disappeared with income ≥US$200,000 (CGMs: 47.5% for black vs 43.1% for white; pumps: 45.9% for black vs 38.3% for white, p=0.45 and p=0.57, respectively). Conclusions In a cohort of commercially insured youth with T1D, both race and income are important factors that can independently influence the use of diabetes technology. Racial disparities decrease with higher income and disappear at incomes ≥US$200,000. Black youth with income <US$40,000 are at the highest exclusion risk from essential technologies. Greater effort is needed at both the system and individual levels to mitigate these disparities.
Mechanistic classification of isolated severe aortic regurgitation in a contemporary cohort of patients
Unni, Rudy R , Boodhwani, Munir , Jelaidan, Ibrahim , Harnett, David T. , Massalha, Samia , Liang, CF, Prosperi-Porta, Graeme, Glineur, David , Burwash, Ian G. , Chan, Kwan‐Leung , Coutinho, Thais , Fu, Angel , Willner, Nadav , Beauchesne, Luc , Messika-Zeitoun, David , Prosperi‐Porta, Graeme , Messika–Zeitoun, David

European Heart Journal Open | May 2, 2025 | Volume: 5 | Issue: 3 | Pages: No page available

10.1093/ehjopen/oeaf042 | PMID 40370504 Get It

Abstract Aims Aortic regurgitation (AR) arises from leaflet disease and/or dilatation of the functional aortic annulus complex. Understanding the mechanisms of AR informs surgical planning of valve and aorta repair. This study investigates the mechanisms, aetiologies, and outcomes of isolated native severe AR in a consecutive cohort of patients. Methods and results Patients with moderate-to-severe (3+)/severe (4+) native valve AR, identified from our institutional echocardiography database (2014–2018), were included. Exclusions were significant concomitant valve disease, endocarditis, or aortic dissection. AR was classified per the El-Khoury system: Type I (normal leaflet motion: Ia–ascending aorta/sinotubular junction dilatation, Ib–aortic root dilation, Ic–aortic annular dilation), Type II (leaflet prolapse), and Type III (leaflet restriction). Valve anatomy and clinical outcomes, including mortality and surgical intervention, were analyzed. Of 282 patients (77.3% male), 58.5% had multiple AR mechanisms. Type II (leaflet prolapse) was most common (48.6%), followed by Type III (36.2%). Bicuspid aortic valve (BAV) represented 35.5% of the population, with leaflet prolapse observed in 72%. Multiple mechanisms were more frequent in BAV (77% vs. 48%, P &lt; 0.001). After a median follow-up of 4.7 years (available for 97.5% of patients), 158 (57.5%) underwent an intervention with 48.7% having an aortic valve repair or valve-sparing aortic root replacement. Conclusion Although leaflet prolapse (Type II) was the pre-dominant AR mechanism, multiple contributing mechanisms were often present, particularly in BAV patients. Aortic valve repair accounted for nearly half of surgical interventions, underscoring the importance of mechanism identification to optimize repair and avoid valve replacement.
Machine Learning Prediction of Left Ventricular Assist Device Thrombosis from Acoustic Harmonic Power
Carlson, Kent, Dragomir‐Daescu, Dan , Boilson, Barry A. , Carlson, Kent D, Razonable, Raymund R

Bioengineering | May 2, 2025 | Volume: 12 | Issue: 5 | Pages: 484

10.3390/bioengineering12050484 | PMID 40428103 Get It

Left ventricular assist device (LVAD) thrombosis typically presents late and may have devastating consequences for patients. While LVAD pump thrombosis is uncommon with current pump designs, many patients worldwide remain supported with previous generations of LVADs, including the HeartWare device (HVAD). Researchers have focused on investigating the acoustic signatures of LVADs to enable earlier detection and treatment of this condition. This study explored the use of machine learning algorithms to predict thrombosis from harmonic power values determined from the acoustic signatures of a cohort of HVAD patients (n = 11). The current dataset was too small to develop a predictive model for new data, but exhaustive cross validation indicated that machine learning models using the first two or the first three harmonic power values both resulted in reasonable prediction accuracy of the thrombosis outcome. Furthermore, when principal component analysis (PCA) was applied to the harmonic power variables from these promising models, the use of the resulting PCA variables in machine learning models further increased the thrombosis outcome prediction accuracy. K-nearest neighbor (KNN) models gave the best predictive accuracy for this dataset. Future work with a larger HVAD recording dataset is necessary to develop a truly predictive model of HVAD thrombosis. Such a predictive model would provide clinicians with a marker to detect HVAD thrombosis based directly on pump performance, to be used along with current clinical markers.
Navigating Sarcopenia Risks in GLP-1RA Therapy for Advanced Heart Failure
Wang, Winston , Green, Danielle B., Ibrahim, Ramzi, Abdelnabi, Mahmoud , Pham, Hoang Nhat , Forst, Beani, Allam, Mohamed , Sarkis, Patrick , Bcharah, George , Farina, Juan M. , Sorajja, Dan , Arsanjani, Reza , Green, Danielle , Farina, Juan M , Sorajja, Dan , Arsanjani, Reza , Allam, Mohamed N , Nhat, Hoang , Ibrahim, Ramzi

Biomedicines | May 2, 2025 | Volume: 13 | Issue: 5 | Pages: 1108

10.3390/biomedicines13051108 | PMID 40426935 Get It

Cardiac cachexia (CC) is a severe complication of advanced heart failure (HF), characterized by involuntary weight loss and muscle wasting, leading to poor outcomes and higher mortality. Despite its severity, CC remains under-recognized and undertreated, lacking targeted therapies specifically addressing its pathophysiology. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), though beneficial in reducing cardiovascular risk in patients with HF, may exacerbate muscle wasting in cachectic patients, necessitating further investigation. Non-pharmacological strategies, including tailored nutritional support and exercise programs, have shown positive effects on body composition and quality of life in patients with CC. However, there remains a gap in recommendations tailored to preventive strategies and pharmacologic therapies for patients with CC and concomitant GLP-1RA use. This review highlights the multifactorial mechanisms underlying CC and current and emerging therapeutic approaches for mitigating HF-related sarcopenia while on GLP-1RAs.